Nov 11 2009
QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment.
John R. Lyon, CEO of Lerner Medical, said, "Levia® is purpose-designed to allow the approximately 6 million Americans suffering from chronic small area and scalp psoriasis to treat themselves, under the direction of their physician, with a clinically proven, non-systemic UVB therapy that is both ultra-convenient and extremely cost-effective. We have recently received clearance to market from the FDA and we plan to launch Levia® in the first quarter of 2010."
"It is a privilege to have been chosen to work in partnership with Lerner Medical on such an important and much needed medical innovation," said Dave Skibinski, President and CEO, QuantumMethod. "This assignment will allow us to leverage our extensive medical products knowledge along with our skills in branding, website development, medical communications, trade show productions, social media, and public relations. QuantumMethod will provide the strategy and creative support to differentiate and position the Levia brand for commercial success, both now and for years to come."
SOURCE: QuantumMethod
Pregnant women with autoimmune conditions at a greater risk of developing adverse pregnancy outcomes, study suggests